AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Industrial Minerals Ltd

0.120

0.000

Volume:11.77K

Turnover:1.41K

Market Cap:9.64M

PE:-4.01

High:0.120

Open:0.120

Low:0.120

Close:0.120

52wk High:0.230

52wk Low:0.090

Shares:80.32M

Float Shares:42.54M

Volume Ratio:0.50

T/O Rate:0.03%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.030

ROE:-81.99%

ROA:-44.01%

PB:3.29

PE(LYR):-4.02

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development

D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002

Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs

Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IND.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IND.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","market":"AU","secType":"STK","nameCN":"Industrial Minerals Ltd","latestPrice":0.12,"timestamp":1770354720000,"preClose":0.12,"halted":0,"volume":11767,"delay":0,"changeRate":0,"nameEN":"Industrial Minerals Ltd","floatShares":42536073,"shares":80322500,"eps":-0.029899,"marketStatus":"Market Closed","change":0,"latestTime":"02-06 16:12:00 AEDT","open":0.12,"high":0.12,"low":0.12,"amount":1412,"amplitude":0,"askPrice":0.14,"askSize":10000,"bidPrice":0.11,"bidSize":7022,"shortable":3,"etf":0,"ttmEps":-0.029899,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.12,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":0.499388868892963,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IND.AU\",,,,,undefined,":{"symbol":"IND.AU","floatShares":42536073,"roa":"-44.01%","roe":"-81.99%","lyrEps":-0.02987,"volumeRatio":0.499388868892963,"shares":80322500,"dividePrice":0,"high":0.12,"amplitude":0,"preClose":0.12,"low":0.12,"week52Low":0.09,"pbRate":"3.29","psRate":"11515.77","week52High":0.23,"institutionHeld":0,"latestPrice":0.12,"committee":-0.17495,"eps":-0.029899,"divideRate":0,"volume":11767,"delay":0,"ttmEps":-0.029899,"open":0.12,"prevYearClose":0.13,"prevWeekClose":0.12,"prevMonthClose":0.12,"prevQuarterClose":0.13,"fiveDayClose":0.12,"twentyDayClose":0.12,"sixtyDayClose":0.14},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IND.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IND.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IND.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2604195420","title":"Ascletis Selects a Next-Generation Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2604195420","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604195420?lang=en_us&edition=fundamental","pubTime":"2026-01-20 17:00","pubTimestamp":1768899600,"startTime":"0","endTime":"0","summary":"- In head-to-head non-human primate  studies, average observed half-life of ASC37 was approximately 17 days, 7-fold longer than retatrutide, which supports once-monthly subcutaneous  dosing in humans.- ASC37's average in vitro activity was approximately 5-, 4-, and 4-fold more potent than retatrutide for GLP-1R, GIPR and GCGR, respectively.- Submission of an Investigational New Drug Application  to the U.S. Food and Drug Administration  for ASC37 injection is expected in the second quarter of 2026.HONG KONG, Jan. 20, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  announces that it has selected ASC37 injection, a next-generation, once-monthly, subcutaneously administered GLP-1R/GIPR/GCGR[1] triple peptide agonist, as a clinical development candidate. Ascletisexpects to submit an Investigational New Drug Applicationto the U.S. Food and Drug Administrationfor ASC37 injection for the treatment of obesity in the second quarter of 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-selects-a-next-generation-once-monthly-subcutaneously-administered-glp-1rgiprgcgr-triple-peptide-agonist-asc37-for-clinical-development-302665199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GIPR","BK4160","IND","BK7095","GLP","BK4144","IND.AU","BK4590"],"gpt_icon":0},{"id":"2604903587","title":"D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002","url":"https://stock-news.laohu8.com/highlight/detail?id=2604903587","media":"prnewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604903587?lang=en_us&edition=fundamental","pubTime":"2026-01-19 09:00","pubTimestamp":1768784400,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan. 19, 2026 /PRNewswire/ -- D3 Bio, a global clinicalstage biotechnology company focused on developing transformative oncology therapeutics, today announced that the U.S. Food and Drug Administration  has cleared two Investigational New Drug  applications:. D3S003 — aKRAS G12D inhibitor — enabling the start of a Phase 1 firstinhuman clinical trial.A Phase 2 combination trial evaluating D3S001 , the Company's nextgeneration KRAS G12C inhibitor, in combination with D3S002, a selective oral ERK1/2 inhibitor.D3S003 is an orally bioavailable, allelespecific KRAS G12D inhibitor that targets both the GDPbound  and GTPbound  conformations. Preclinical data demonstrate a differentiated, bestinclass profile with potent antitumor activity, favorable druglike characteristics, and a promising safety margin. With FDA clearance received, D3 Bio will advance D3S003 into a Phase 1 firstinhuman study in patients with advanced solid tumors harboring KRAS G12D mutations.","market":"sh","thumbnail":"https://mma.prnewswire.com/media/2758996/D3_BIO_DeShengJi_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2758996/D3_BIO_DeShengJi_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/d3-bio-receives-us-fda-clearance-for-two-ind-applications-enabling-phase-1-trial-of-d3s003-and-phase-2-combination-study-of-elisrasib-d3s001-with-d3s002-302664023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1854104046.USD","LU1548497426.USD","BK7095","BK4585","LU1861220033.SGD","LU2357305700.SGD","LU0124384867.USD","LU1861215975.USD","ON","LU1720051108.HKD","IND","IND.AU","LU1861219969.SGD","IE00BZ199S13.USD","LU1861214812.USD","BK4512","LU0724618433.USD","LU2360107325.USD","BK4588","BK4141","IE00BD6J9T35.USD","BK4605","LU0348723411.USD","IE00BFMHRM44.USD","LU1854103824.USD","LU2298322129.HKD","LU1720051017.SGD","LU1978683503.SGD"],"gpt_icon":0},{"id":"2603400937","title":"Antengene Presents at JPM: Strong Clinical Data Update and Strategic Focus on Next-Generation ADCs and TCEs","url":"https://stock-news.laohu8.com/highlight/detail?id=2603400937","media":"prnewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603400937?lang=en_us&edition=fundamental","pubTime":"2026-01-16 09:00","pubTimestamp":1768525200,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, Jan. 16, 2026 /PRNewswire/ -- Antengene Corporation Limited , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines forautoimmune disease, solid tumors and hematological malignancies indications, announced that it recently presented at the 44th Annual J.P. Morgan Healthcare Conference held in San Francisco. At the conference, Antengene shared the latest data and clinical development plans for its core clinical asset, ATG-022 , as well as R&D progress on ATG-125 , its steric hindrance masking AnTenGager T cell engager  platform, and other key preclinical programs.Advancing clinical development across 1L to 3L gastric cancer: Antengene is currently conducting the Phase I/II CLINCH study and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/antengene-presents-at-jpm-strong-clinical-data-update-and-strategic-focus-on-next-generation-adcs-and-tces-302662555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU0211328371.USD","LU0106261372.USD","LU1084165304.USD","LU2106854487.HKD","LU0251132253.USD","LU2756315664.SGD","IE0034235188.USD","CRS.AU","CR","IE00BN8TJ469.HKD","LU1064131342.USD","LU0345769631.USD","LU0006306889.USD","LU0106831901.USD","LU0820561818.USD","LU0683600562.USD","ORR","LU0417517546.SGD","LU1670627923.USD","ACR.AU","IE00BHPRN162.USD","LU0820562030.AUD","IE00BKVL7J92.USD","LU1629891620.HKD","LU2264538146.SGD","BK4534","LU2430703095.HKD","IE00B3S45H60.SGD","CRS","IE00BFXG1179.USD","IND","LU0345770308.USD","LU0345770993.USD","LU2023250843.SGD","ORR.AU","LU0170899867.USD","LU0787776722.HKD","ACR","LU2065731478.USD","IE0034235295.USD","IND.AU","LU0943347566.SGD","LU1244550494.USD","LU1974910355.USD","BK4581","LU0868494617.USD","BK7508","LU2746668461.USD"],"gpt_icon":0},{"id":"2603620144","title":"Belief BioMed Congratulates Partner AskBio on IND Acceptance by FDA for Investigational Gene Therapy for Late-Onset Pompe Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2603620144","media":"prnewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603620144?lang=en_us&edition=fundamental","pubTime":"2026-01-15 12:11","pubTimestamp":1768450260,"startTime":"0","endTime":"0","summary":"SHANGHAI, Jan. 15, 2026 /PRNewswire/ -- AskBio Inc. , a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, recently announced that the United States Food and Drug Administration  has accepted its Investigational New Drug  application for AB-1009, an investigational adeno-associated virus  gene therapy being developed for the treatment of late-onset Pompe disease. With this announcement, the AB-1009 program advances to Phase 1/2, and AskBio initiates a clinical trial in the United States to explore the safety of AB-1009. The company anticipates recruiting its first patient in early 2026 [1].In September 2024, Belief BioMed  and AskBio entered astrategic collaboration to explore the potential for new gene therapies [2]. BBM granted AskBio a sublicense to use the proprietary AAV capsid in the AB-1009 program and provided AAV vector production services. Within the collaborative development framework, BBM worked closely with the AskBio team, and its co","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/belief-biomed-congratulates-partner-askbio-on-ind-acceptance-by-fda-for-investigational-gene-therapy-for-late-onset-pompe-disease-302661902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GAA","BLA.AU","BK7095","IND","IND.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IND.AU\",params:#limit:6,delay:true,,,undefined,":[]}}